pharma news

News

Changes at the top of Sarepta, Alkermes, as CEOs depart

Two long-serving pharma CEOs have announced their departures, as Sarepta's Doug Ingram and Alkermes' Richard Pops announce their retirement.

News

Novo Nordisk beefs up in oral obesity drugs with Vivtex deal

Novo Nordisk is leaving no stone unturned in its bid to maintain its position in weight-loss therapies as it signs a $2.1bn alliance with Vivtex.

News

GSK grows pipeline with 35Pharma takeover, Frontier deal

GSK CEO Luke Miels signs a pair of pipeline-expanding deals, and the first acquisition on his watch, as the group prepares for a looming patent cliff.

News

Black background scattered with red 'SALE' tickets

Novo Nordisk to cut GLP-1 prices in tough US market

Novo Nordisk has turned to pricing as a means to shore up its position in the increasingly competitive market for GLP-1 agonist therapies in the US.

News

Astellas bets on Vir cancer drug, and other licensing deals

Our latest round-up of pharma licensing deals features assets from Vir Biotech, Harbour BioMed, Unnatural Products, Genhouse, and CSL.

News

In brief SOTU remarks, Trump asks Congress to "codify" MFN

In a speech at least nominally focused on the economy and affordability, President Trump put surprisingly little emphasis on his drug pricing efforts.

Changes at the top of Sarepta, Alkermes, as CEOs depart

Novo Nordisk beefs up in oral obesity drugs with Vivtex deal

GSK grows pipeline with 35Pharma takeover, Frontier deal

Novo Nordisk to cut GLP-1 prices in tough US market

Astellas bets on Vir cancer drug, and other licensing deals

In brief SOTU remarks, Trump asks Congress to "codify" MFN

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

pharma news

Editor's Picks